Grant Bishop

Tuesday, 10 November 2026 · Markets closed · Edition 20

Abbott

ABT

Abbott makes diagnostic tests, medical devices, nutrition products and diabetes monitors that hospitals and patients use daily. We follow it because the spread of weight-loss drugs may change demand for the care and services it provides.

Checked against the company's own business description in its latest annual filing. · entry updated 2026-10-19
Ticker
ABT
Exchange
—
Price
—
Change
—
As of
—
Market cap
—
EV/EBIT
—
P/E NTM
—
FCF yield
—
Net debt/EBITDA
—
Next earnings
—

Last refreshed from 10-Q filed (EDGAR)

Follow · Add to calendar · Daily window

The living report

Bears on our standing view that AI's economy-wide productivity lift does not arrive before 2028. It is proved wrong if productivity jumps much sooner than we expect, or adoption stops spreading.

last revised 19 Oct 2026 · next scheduled disclosure not yet announced
The full report

Members: queues this company for a report on a coming night.

The market record

Free during the preview. Each figure shows only where two independent data providers, Massive and Yahoo, agree on it to the cent; a figure they do not agree on is left out. Dated, not live. It describes; it does not recommend.

Last close$110.51
close of 9 Nov 2026 · Massive and Yahoo agree
The day's range$108.93 – $111.01
9 Nov 2026 · both providers agree
52-week range$81.97 – $132.03
intraday low 11 May 2026 · intraday high 18 Nov 2025 · 251 sessions to 9 Nov 2026 · both providers agree
Market value$191.4 billion
the 9 Nov 2026 close × 1,731,941,601 shares outstanding on the 10-Q cover, as of 30 Sep 2026
$

Enter any price. The page shows the multiple on the forward estimate on file and where that price sits in the 52-week range. It computes; it does not recommend.

Filings

Newest first, from EDGAR. Where a piece read a filing, one line of what it said.

4 Nov 202610-Q · period ending 30 Sep 2026
21 Oct 20268-K · period ending 21 Oct 2026
21 Oct 20268-K · period ending 21 Oct 2026
20 Aug 20268-K · period ending 20 Aug 2026
On 20 August Deere reported farm sales down and construction sales up. the piece
28 Jul 202610-Q · period ending 30 Jun 2026
16 Jul 20268-K · period ending 16 Jul 2026
On 16 July Abbott reported falling nutrition volumes alongside 13 percent cancer-diagnostics growth. the piece
29 Apr 202610-Q · period ending 31 Mar 2026
27 Apr 20268-K · period ending 24 Apr 2026
17 Apr 20268-K · period ending 10 Apr 2026
16 Apr 20268-K · period ending 16 Apr 2026
23 Mar 20268-K · period ending 23 Mar 2026
9 Mar 20268-K · period ending 9 Mar 2026
26 Feb 20268-K · period ending 23 Feb 2026
20 Feb 202610-K · period ending 31 Dec 2025
20 Feb 20268-K · period ending 20 Feb 2026
22 Jan 20268-K · period ending 22 Jan 2026
12 Dec 20258-K · period ending 12 Dec 2025
21 Nov 20258-K · period ending 18 Nov 2025
20 Nov 20258-K · period ending 19 Nov 2025
29 Oct 202510-Q · period ending 30 Sep 2025
15 Oct 20258-K · period ending 15 Oct 2025
30 Jul 202510-Q · period ending 30 Jun 2025
17 Jul 20258-K · period ending 17 Jul 2025
1 May 20258-K · period ending 25 Apr 2025
30 Apr 202510-Q · period ending 31 Mar 2025
28 Apr 20258-K · period ending 25 Apr 2025
16 Apr 20258-K · period ending 16 Apr 2025
21 Feb 202510-K · period ending 31 Dec 2024
22 Jan 20258-K · period ending 22 Jan 2025
15 Nov 20248-K · period ending 12 Nov 2024

Where it sits in the frame

Reports next

not yet announced

Latest disclosed

10-Q · filed 2026-07-28 · period ending 2026-06-30

Read the filing

Machine-readable

/index/ABT.json

What it has disclosed

Newest first. Every figure traces to a filing; "Show sources" shows which.

30 Sep 2026Abbott Q3 2026 adjusted diluted EPS guidance, low end: $1.38Abbott Reports Second-Quarter 2026 Results (Exhibit 99.1), SEC Form 8-K, 16 Jul 2026 · filing
30 Sep 2026Abbott Q3 2026 adjusted diluted EPS guidance, high end: $1.46Abbott Reports Second-Quarter 2026 Results (Exhibit 99.1), SEC Form 8-K, 16 Jul 2026 · filing
30 Jun 2026Abbott reported sales growth, Q2 2026: 13.0 percentAbbott Reports Second-Quarter 2026 Results (Exhibit 99.1), SEC Form 8-K, 16 Jul 2026 · filing (vs Q2 2025)
30 Jun 2026Abbott comparable sales growth, Q2 2026: 4.8 percentAbbott Reports Second-Quarter 2026 Results (Exhibit 99.1), SEC Form 8-K, 16 Jul 2026 · filing (vs Q2 2025)
30 Jun 2026Abbott Worldwide Nutrition sales, Q2 2026: 3.6 percentAbbott Reports Second-Quarter 2026 Results (Exhibit 99.1), SEC Form 8-K, 16 Jul 2026 · filing (comparable basis, vs Q2 2025)

Mentioned in

Every piece that names this company, newest first: what it said, and the standing view it bore on. Written when the piece is committed; never edited, never removed.

Same question

Other companies under Whose care and services may the drugs change?

This entry

19 Oct 2026Entry rewritten in plain words: what the company sells, and why we follow it.
12 Oct 2026Verified against the 10-Q filed 2026-07-28 at launch.

Prices on this page are dated market records, shown free during the preview, each confirmed by two independent data providers. None is a recommendation.

Follow Abbott. The weekly piece, and a note when a filing moves it.

Record

Written according to the Grant Bishop standard — machine-researched, machine-checked, human-judged; then read and committed by the publisher. Every number traces to a filing or a dated market record; every claim carries a date and what would prove it wrong.

Verification
multi-source verified, machine-drafted, human-gated
As of
2026-07-28
Position disclosure
The publisher holds index-level U.S. equity exposure and no direct position in any single name discussed.
Not advice
General commentary for a general audience. Not advice for your situation.
Sources (12)